Shilpa Medicare Limited (BOM:530549)
India
· Delayed Price · Currency is INR | Market Cap | 62.71B |
| Revenue (ttm) | 12.49B |
| Net Income (ttm) | 882.87M |
| Shares Out | 86.80M |
| EPS (ttm) | 9.31 |
| PE Ratio | 77.59 |
| Forward PE | 28.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,500 |
| Average Volume | 14,656 |
| Open | 684.05 |
| Previous Close | 677.00 |
| Day's Range | 668.30 - 685.50 |
| 52-Week Range | 419.10 - 959.95 |
| Beta | 0.51 |
| RSI | 54.51 |
| Earnings Date | May 23, 2025 |
About Shilpa Medicare
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, recombinant albumin in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatini... [Read more]
Financial Performance
Financial StatementsNews
Shilpa Medicare settles Celltrion arbitration case with $3.4 million agreement
Shilpa Medicare Limited has entered into a settlement agreement with Celltrion Inc., a South Korea-based pharmaceutical company, thereby resolving an ongoing arbitration dispute. The company informed ...
Shilpa Medicare gets USFDA approval for Varenicline tablets for smoking cessation
Shilpa Medicare Limited, a Raichur-based pharmaceutical company, announced on April 9 that it has received the much-anticipated approval from the U.S. Food and Drug Administration (USFDA) for its Vare...
Shilpa Medicare’s partner Amneal launches BORUZU in US
Shilpa Medicare’s marketing partner, Amneal Pharmaceuticals, has launched BORUZU™ (Bortezomib for Injection, 3.5mg/1.4ml) in the U.S. market. This ready-to-use oncology product is designed for subcuta...
Shilpa Medicare subsidiary signs exclusive deal with Switzerland-based mAbTree Biologics AG
Shilpa Biologicals Pvt Ltd, a subsidiary of Shilpa Medicare Limited, has entered an exclusive co-development and commercialization agreement with Switzerland-based mAbTree Biologics AG for a breakthro...
Shilpa Medicare’s subsidiary clears USFDA inspection with zero observations for second consecutive time
Shilpa Medicare Limited has announced that the United States Food and Drug Administration (USFDA) has successfully completed an inspection at Unit-2 of Shilpa Pharma Lifesciences Limited, a wholly own...
Shilpa Medicare secures CDSCO approval for Phase 3 clinical trial
Shilpa Medicare Limited has received approval from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) for its IND – Nor Ursodeoxycholic Acid Tablets 500 mg. ...
Shilpa Medicare Q3 results: Revenue up 11% YoY to Rs 319 crore, Net Profit up 595% YoY
Shilpa Medicare reports Q3 earnings – Key Financial Highlights (Q3 FY25): Net Profit: ₹32 crore, a significant increase compared to ₹4.6 crore in Q3 FY24, marking a strong turnaround. Revenue: ₹319 cr...
Shilpa Medicare subsidiary receives CEP from EDQM for Teriflunomide API
Shilpa Pharma Lifesciences Limited, a wholly-owned subsidiary of Shilpa Medicare Limited, has been awarded the Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines...
Shilpa Medicare secures Portugal marketing authorization for Tadalafil Orodispersible Films
Shilpa Medicare Limited, based in Raichur, Karnataka, has achieved a significant milestone by receiving Marketing Authorization from Portugal for its Tadalafil Orodispersible Films (20 mg). This innov...
Shilpa Medicare receives GMP certification for units IV and VII in Telangana
Shilpa Medicare Ltd. has successfully received Good Manufacturing Practice (GMP) approval from the Ministry of Health, Belarus, for its Unit IV in Jadcherla and Unit VII in Nacharam, Hyderabad. This c...
Shilpa Medicare secures Europe GMP certification for Unit VII, Hyderabad
Shilpa Medicare Limited has announced the receipt of the Good Manufacturing Practice (GMP) Certification for its Unit VII in Nacharam, Hyderabad, from the European Medicines Agency (EMA), Austria. Thi...
Shilpa Medicare Receives Approval for Phase III Clinical Trials of Recombinant Human Albumin
Shilpa Medicare Ltd. has announced that the Subject Expert Committee (Haematology) has approved the company to conduct Phase III clinical trials for its Recombinant Human Albumin (rHA) 20%. This appro...
Shilpa Pharma Lifesciences receives CEP for API, Nifedipine from EDQM
Shilpa Pharma Lifesciences Limited, a 100% subsidiary of Shilpa Medicare Limited, has recently received the prestigious Certificate of Suitability (CEP) from the European Directorate for the Quality o...
Shilpa Medicare shares surge over 4% as subsidiary secures CEP for Octreotide API
Shares of Shilpa Medicare gained attention on Tuesday, November 19, following a major milestone for its 100% subsidiary, Shilpa Pharma Lifesciences Limited, which received a Certificate of Suitability...
Stocks In Focus Today, November 19: GMR Airports, Shilpa Medicare, ITI, PG Electroplast, AstraZeneca Pharma
Here are the key stocks to watch out for in today's trading session based on the latest updates and developments
Shilpa Medicare shares surge 4% on strong Q2 FY25 financial performance
Shilpa Medicare posted impressive Q2 FY25 results, sparking a 4% surge in its stock price and making it a stock to watch. The company reported significant gains in revenue, profitability, and margins,...
Stock to Watch: Shilpa Medicare reports robust Q2 FY25 performance with 11% revenue growth and 1008% PAT increase
Shilpa Medicare has posted strong financial results for Q2 FY25, demonstrating significant growth across key metrics. The company achieved notable improvements in revenue, profitability, and margins, ...
Shilpa Medicare announces USFDA acceptance of NDA for Oxylanthanum Carbonate filed by Unicycive
Shilpa Medicare has announced that the USFDA has accepted the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) filed by Unicycive for hyperphosphatemia in chronic kidney disease (CKD) patie...
Shilpa Medicare shares jump 3% as CDMO customer secures USFDA Fast Track Designation for GBM Drug
Shilpa Medicare shares jumped more than 3% after its CDMO customer received Fast Track Designation from the US FDA for their investigational drug for Glioblastomaa (GBM). SML offers end-to-end solutio...
Shilpa Medicare shares surge over 2% after arm gets CEP from EDQM for Desmopressin
Shilpa Medicare shares jumped more than 2% in morning trade after its subsidiary Shilpa Pharma Lifesciences Limited received a Certificate of Suitability (CEP) from EDQM for its API, Desmopressin. Shi...
Shilpa Pharma Lifesciences receives CEP for Desmopressin from EDQM
Shilpa Medicare Limited’s subsidiary, Shilpa Pharma Lifesciences Limited, has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare (EDQM)...
Shilpa Pharma Lifesciences gets certificate of suitability from EDQM for API, Desmopressin
Shilpa Pharma Lifesciences Limited, a subsidiary of Shilpa Medicare Limited, has recently informed exchanges that the company got a Certificate of Suitability (CEP) from EDQM for its API, Desmopressin...
Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as new CEO
Shilpa Biologicals Private Limited, a wholly owned subsidiary of Shilpa Medicare Limited, has appointed Dr. Sridevi Khambhampaty as its new Chief Executive Officer (CEO), effective from September 19, ...
Shilpa Medicare shares rise 4% to after Antique initiates ‘Buy’ rating with target price of ₹1300
Shilpa Medicare’s stock surged by 3.87% to ₹917 on the NSE at 9:22 AM after Antique Stock Broking initiated a ‘Buy’ rating with a target price of ₹1300. The firm cited Shilpa Medicare’s strong formula...
Shilpa Medicare Stock: Share price surges 9% this week on USFDA approval for Bortezomib Injection
Following the company’s statement that the U.S. Food and Drug Administration (FDA) has approved its Bortezomib injection under New Drug Application (NDA) 212782, Shilpa Medicare Ltd.’s stock price inc...